SG Americas Securities LLC Buys 3,000 Shares of Genelux Co. (NASDAQ:GNLX)

SG Americas Securities LLC raised its stake in Genelux Co. (NASDAQ:GNLX) by 45.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,605 shares of the company’s stock after purchasing an additional 3,000 shares during the quarter. SG Americas Securities LLC’s holdings in Genelux were worth $135,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the stock. California State Teachers Retirement System bought a new position in shares of Genelux during the 2nd quarter worth approximately $30,000. Amalgamated Bank boosted its stake in shares of Genelux by 250.8% during the 3rd quarter. Amalgamated Bank now owns 1,077 shares of the company’s stock worth $26,000 after acquiring an additional 770 shares during the period. Tower Research Capital LLC TRC bought a new position in shares of Genelux during the 1st quarter worth approximately $32,000. Legal & General Group Plc boosted its stake in shares of Genelux by 535.2% during the 3rd quarter. Legal & General Group Plc now owns 1,696 shares of the company’s stock worth $41,000 after acquiring an additional 1,429 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in Genelux by 2,105.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 2,205 shares of the company’s stock worth $72,000 after purchasing an additional 2,105 shares during the last quarter. 37.33% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Benchmark reissued a “speculative buy” rating and set a $30.00 price target on shares of Genelux in a report on Wednesday, April 3rd. HC Wainwright dropped their price target on Genelux from $35.00 to $32.00 and set a “buy” rating for the company in a report on Tuesday, April 2nd.

Genelux Price Performance

NASDAQ:GNLX opened at $3.62 on Thursday. The stock has a 50 day simple moving average of $6.36 and a 200 day simple moving average of $11.70. Genelux Co. has a 1-year low of $3.42 and a 1-year high of $40.98.

Genelux Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.